NCT00600782View on ClinicalTrials.gov

Immunogenicity and Safety of a Candidate Tuberculosis (TB) Vaccine Given to Healthy Adults in a TB-endemic Region

PHASE2CompletedINTERVENTIONAL

Enrollment

45

Participants

Timeline

Start Date

February 5, 2008

Primary Completion Date

December 19, 2008

Study Completion Date

December 19, 2008

Conditions

Tuberculosis (TB)Tuberculosis Vaccines

Interventions

BIOLOGICAL

GSK Biologicals' Candidate Tuberculosis (TB) Vaccine (692342)

Intramuscular injection, 2 doses at 0, 1 month

Trial Locations (1)

6850

GSK Investigational Site, Worcester

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY